Effect of Clozapine on Neutrophil Kinetics in Rabbits

被引:18
作者
Iverson, Suzanne [1 ]
Kautiainen, Antti [1 ]
Ip, Julia [1 ]
Uetrecht, Jack P. [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada
基金
加拿大健康研究院;
关键词
INDUCED AGRANULOCYTOSIS; IN-VITRO; LYMPHOCYTE KINETICS; FLUORESCENT DYE; RISK-FACTOR; CELLS; GRANULOCYTES; METABOLITES; DEFICIENCY; HYPOTHESIS;
D O I
10.1021/tx100035k
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Clozapine is an atypical antipsychotic drug effective in the treatment of refractory schizophrenia; however, its use is limited due to its propensity to cause agranulocytosis in some patients. Little is known about the mechanism of idiosyncratic drug-induced agranulocytosis, in part because of the lack of a valid animal model. Clozapine is oxidized by activated human neutrophils and bone marrow cells to a reactive nitrenium ion by the myeloperoxidase-hydrogen peroxide system of neutrophils. This reactive metabolite has been shown in vitro to induce the apoptosis of neutrophils and bone marrow cells. While in vitro studies demonstrated the toxic potential of clozapine upon oxidation, it is not clear if similar conditions occur in vivo. In response to the difficulties encountered with detecting apoptotic neutrophils in vivo, we conducted a series of studies in rabbits using two fluorescent cell-labeling techniques to study the effect of clozapine treatment on neutrophil kinetics, that is, their rates of production and removal from circulation. The fluorescein dye, 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE), was used as a general cell label to measure the half-life of neutrophils in blood. In addition, the thymidine analogue, 5-bromo-2-deoxyuridine (BrdU), was used to label dividing cells, thus enabling the measurement of the efflux of neutrophils from the bone marrow. Clozapine, indeed, increased the rate of both the release of neutrophils from the bone marrow and their subsequent disappearance from circulation. Failure of the bone marrow to compensate for a shorter neutrophil half-life could lead to agranulocytosis. Alternatively, the damage to neutrophils caused by clozapine could, in some patients, lead to an immune-mediated response against neutrophils resulting in agranulocytosis.
引用
收藏
页码:1184 / 1191
页数:8
相关论文
共 29 条
[1]  
ALVIR JMJ, 1995, PSYCHOPHARMACOL BULL, V31, P311
[2]   Quantifying lymphocyte kinetics in vivo using carboxyfluorescein diacetate succinimidyl ester (CFSE) [J].
Asquith, B ;
Debacq, C ;
Florins, A ;
Gillet, N ;
Sanchez-Alcaraz, T ;
Mosley, A ;
Willems, L .
PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2006, 273 (1590) :1165-1171
[3]   Lymphocyte kinetics: the interpretation of labelling data [J].
Asquith, B ;
Debacq, C ;
Macallan, DC ;
Willems, L ;
Bangham, CRM .
TRENDS IN IMMUNOLOGY, 2002, 23 (12) :596-601
[4]   Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland [J].
Atkin, K ;
Kendall, F ;
Gould, D ;
Freeman, H ;
Lieberman, J ;
OSullivan, D .
BRITISH JOURNAL OF PSYCHIATRY, 1996, 169 (04) :483-488
[5]  
BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746
[6]   Tracking of leukocyte recruitment into tissues of mice by in situ labeling of blood cells with the fluorescent dye CFDA SE [J].
Becker, HM ;
Chen, M ;
Hay, JB ;
Cybulsky, MI .
JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 286 (1-2) :69-78
[7]   THE MAJOR HISTOCOMPATIBILITY COMPLEX REGION MARKED BY HSP70-1 AND HSP70-2 VARIANTS IS ASSOCIATED WITH CLOZAPINE-INDUCED AGRANULOCYTOSIS IN 2 DIFFERENT ETHNIC-GROUPS [J].
CORZO, D ;
YUNIS, JJ ;
SALAZAR, M ;
LIEBERMAN, JA ;
HOWARD, A ;
AWDEH, Z ;
ALPER, CA ;
YUNIS, EJ .
BLOOD, 1995, 86 (10) :3835-3840
[8]   Estimating average cellular turnover from 5-bromo-2′-deoxyuridine (BrdU) measurements [J].
De Boer, RJ ;
Mohri, H ;
Ho, DD ;
Perelson, AS .
PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2003, 270 (1517) :849-858
[9]   Antipsychotic drugs result in the formation of immature neutrophil leucocytes in schizophrenic patients [J].
Delieu, JM ;
Badawoud, M ;
Williams, MA ;
Horobin, RW ;
Duguid, JK .
JOURNAL OF PSYCHOPHARMACOLOGY, 2001, 15 (03) :191-194
[10]  
Gardner I, 1998, MOL PHARMACOL, V53, P999